| Literature DB >> 34737870 |
Davies Adeloye1, Dhiraj Agarwal2, Peter J Barnes3, Marcel Bonay4, Job F van Boven5, Jamie Bryant6, Gaetano Caramori7, David Dockrell8, Anthony D'Urzo9, Magnus Ekström10, Gregory Erhabor11, Cristóbal Esteban12, Catherine M Greene13, John Hurst14, Sanjay Juvekar2, Ee Ming Khoo15, Fanny W Ko16, Brian Lipworth17, Jose L López-Campos18, Matthew Maddocks19, David M Mannino20, Fernando J Martinez21, Miguel A Martinez-Garcia22, Renae J McNamara23, Marc Miravitlles24, Hilary Pinnock1, Alison Pooler25, Jennifer K Quint3, Peter Schwarz26, George M Slavich27, Peige Song28, Andrew Tai29, Henrik Watz30, Jadwiga A Wedzicha3, Michelle C Williams31, Harry Campbell1, Aziz Sheikh1, Igor Rudan1.
Abstract
BACKGROUND: The global prevalence of chronic obstructive pulmonary disease (COPD) has increased markedly in recent decades. Given the scarcity of resources available to address global health challenges and respiratory medicine being relatively under-invested in, it is important to define research priorities for COPD globally. In this paper, we aim to identify a ranked set of COPD research priorities that need to be addressed in the next 10 years to substantially reduce the global impact of COPD.Entities:
Mesh:
Year: 2021 PMID: 34737870 PMCID: PMC8542376 DOI: 10.7189/jogh.11.15003
Source DB: PubMed Journal: J Glob Health ISSN: 2047-2978 Impact factor: 7.664
Top 20 research ideas by their overall Research Priority Scores (RPS) and Average Expert Agreement (AEA)
| Rank | Research idea | Sub-theme | Answerable? | Effective? | Feasible? | Deliverable? | Impact? | Equity? | Rps | Aea |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Developing new strategies (including new combinations of pharmacological and non-pharmacological strategies) to improve smoking cessation | III | 0.952 | 0.967 | 0.790 | 0.790 | 0.903 | 0.806 |
| 0.779 |
| 2 | Identifying feasible and effective modes of delivery of pulmonary rehabilitation in low-resource settings | III | 0.935 | 0.667 | 0.935 | 0.903 | 0.823 | 0.903 |
| 0.779 |
| 3 | Identifying optimal screening method for COPD in primary care | V | 0.938 | 0.773 | 0.969 | 0.924 | 0.667 | 0.848 |
| 0.814 |
| 4 | Identifying feasible strategies to improve access to pulmonary rehabilitation for COPD patients whilst retaining cost-effectiveness | III | 0.953 | 0.710 | 0.953 | 0.891 | 0.766 | 0.813 |
| 0.779 |
| 5 | Identifying approached to scale-up of delivery of effective pulmonary rehabilitation in low resource settings to meet the burden of breathlessness | III | 0.900 | 0.672 | 0.933 | 0.850 | 0.817 | 0.900 |
| 0.730 |
| 6 | Defining the most affordable, accurate and reliable diagnostic process for respiratory symptoms in low-resource settings based on evidence | V | 0.891 | 0.758 | 0.823 | 0.917 | 0.742 | 0.935 |
| 0.755 |
| 7 | Exploring the non-smoking risk factors for the development of COPD (eg, premature birth, childhood asthma, genes, biomass fumes exposure, atmospheric pollution, etc.) | I | 0.909 | 0.855 | 0.844 | 0.797 | 0.774 | 0.875 |
| 0.775 |
| 8 | Identifying optimal diagnostic approach for COPD in low-resource settings | V | 0.938 | 0.742 | 0.813 | 0.938 | 0.703 | 0.875 |
| 0.779 |
| 9 | Improved understanding of COPD risk factors and their association with COPD incidence and exact effects | I | 0.894 | 0.859 | 0.984 | 0.797 | 0.734 | 0.734 |
| 0.770 |
| 10 | Identifying optimal approaches to training physicians, health care workers, policy makers and the community in low resource settings about COPD and its risk factors | III | 0.894 | 0.797 | 0.906 | 0.813 | 0.750 | 0.813 |
| 0.779 |
| 11 | Health policy and systems research on feasibility of establishing pulmonary rehabilitation centers in the communities | III | 0.906 | 0.645 | 0.969 | 0.891 | 0.742 | 0.781 |
| 0.765 |
| 12 | Identifying strategies that are effective and cost-effective in reducing anxiety and depression among individuals with COPD | III | 0.933 | 0.583 | 0.919 | 0.800 | 0.919 | 0.742 |
| 0.672 |
| 13 | Developing guidelines for health practitioners in low resource settings to diagnose and treat/manage their COPD patients | V | 0.969 | 0.700 | 0.875 | 0.906 | 0.633 | 0.766 |
| 0.745 |
| 14 | Identifying the most cost-effective COPD treatment strategies for low resource settings | III | 0.903 | 0.700 | 0.806 | 0.806 | 0.733 | 0.871 |
| 0.725 |
| 15 | Defining criteria for antibiotics use in acute COPD | III | 0.970 | 0.710 | 0.938 | 0.906 | 0.656 | 0.594 |
| 0.750 |
| 16 | Developing an eHealth pulmonary rehabilitation program that is as effective as regular rehabilitation in both health benefits and costs | III | 0.938 | 0.661 | 0.906 | 0.875 | 0.703 | 0.688 |
| 0.740 |
| 17 | Identifying the most effective e-health, m-health and telemedicine interventions for the management of COPD in primary care | III | 0.938 | 0.613 | 0.906 | 0.891 | 0.719 | 0.688 |
| 0.735 |
| 18 | Identifying feasible and effective means to increase physical activity in patients with newly diagnosed COPD | III | 0.919 | 0.661 | 0.891 | 0.839 | 0.629 | 0.806 |
| 0.711 |
| 19 | Identifying feasible approaches for providing pulmonary rehabilitation in primary care | III | 0.935 | 0.567 | 0.903 | 0.823 | 0.710 | 0.774 |
| 0.711 |
| 20 | Studying the effectiveness of physical activity incentive programs on prevention of hospitalizations due to acute exacerbations of COPD | III | 0.903 | 0.694 | 0.952 | 0.774 | 0.625 | 0.742 |
| 0.711 |
COPD – chronic obstructive pulmonary disease
*Overall Research Priority Score used for the ranking is given in bold.
Bottom 20 research ideas (in descending order) by their overall Research Priority Scores (RPS) and Average Expert Agreement (AEA)
| RANK | RESEARCH IDEA | SUB-THEME | ANSWERABLE? | EFFECTIVE? | FEASIBLE? | DELIVERABLE? | IMPACT? | EQUITY? | RPS | AEA |
|---|---|---|---|---|---|---|---|---|---|---|
| 230 | Synthesizing various lines of evidence to reach a consensus whether COPD is a disease or a disorder | V | 0.365 | 0.111 | 0.278 | 0.259 | 0.111 | 0.333 |
| 0.593 |
| 229 | Evaluating animal models to determine the contributions of new generation of nicotine products | III | 0.556 | 0.308 | 0.482 | 0.315 | 0.125 | 0.310 |
| 0.525 |
| 228 | Evaluating the usefulness of measuring sensory and affective dimension of acute or episodic breathlessness (clinical, spirometry, EEG and fMRI) to differentiate breathlessness from panic in COPD | VI | 0.556 | 0.214 | 0.500 | 0.414 | 0.155 | 0.300 |
| 0.554 |
| 227 | Piloting replacement of diagnosis “COPD” with individual clinical and biological phenotyping | V | 0.571 | 0.293 | 0.500 | 0.310 | 0.172 | 0.310 |
| 0.554 |
| 226 | Studying gene reprogramming of the epithelium in COPD | II | 0.560 | 0.280 | 0.558 | 0.288 | 0.120 | 0.357 |
| 0.495 |
| 225 | Studying if adverse effects of beta agonists, taken in the absence of inhaled corticosteroids, are an unrecognised problem in COPD | III | 0.692 | 0.167 | 0.625 | 0.393 | 0.148 | 0.393 |
| 0.554 |
| 224 | Understanding the basic non-hypoxic pathogenesis of pulmonary hypertension in COPD | II | 0.667 | 0.241 | 0.607 | 0.431 | 0.103 | 0.379 |
| 0.564 |
| 223 | Studying the pathophysiological processes that lead to emphysema, bronchiectasis and chronic bronchitis - are they the same but just affecting different anatomical sites? | II | 0.630 | 0.321 | 0.500 | 0.321 | 0.286 | 0.379 |
| 0.515 |
| 222 | Developing new models of care in COPD based on the coming “silver tsunami” and limited resources | III | 0.500 | 0.308 | 0.407 | 0.407 | 0.385 | 0.500 |
| 0.426 |
| 221 | Studying if chronic non-fully reversible airflow obstruction in never-smokers is really COPD | III | 0.630 | 0.286 | 0.569 | 0.339 | 0.241 | 0.483 |
| 0.515 |
| 220 | Identifying diagnostic tools to distinguish between the true COPD exacerbation and just a 'bad day' | V | 0.569 | 0.323 | 0.583 | 0.552 | 0.155 | 0.367 |
| 0.544 |
| 219 | Exploring if measurement of lung stiffness as reactance area (AX) using impulse oscillometry can identify treatment response to LABA/LAMA or triple therapy in patients with GOLD B/D | III | 0.793 | 0.222 | 0.707 | 0.464 | 0.154 | 0.259 |
| 0.569 |
| 218 | Exploring the basis of day-to-day variability in symptoms (eg, dyspnoea, fatigue, pain, weakness, insomnia, guilt, anxiety, depression, appetite, etc.) in patients with COPD | VI | 0.685 | 0.259 | 0.625 | 0.389 | 0.179 | 0.483 |
| 0.525 |
| 217 | Exploring if COPD with airway mucus hypersecretion and higher risk of dying should be approached as a separate disease | II | 0.565 | 0.328 | 0.583 | 0.533 | 0.300 | 0.367 |
| 0.525 |
| 216 | Identifying biological pathways that underlie different clinical presentations | II | 0.635 | 0.310 | 0.500 | 0.481 | 0.250 | 0.500 |
| 0.461 |
| 215 | Studying the early effects causing a lower maximum lung function at young adulthood and its clinical implications | VI | 0.558 | 0.446 | 0.625 | 0.352 | 0.304 | 0.429 |
| 0.480 |
| 214 | Identifying drivers of epithelial-mesenchymal transition (EMT) in smoking-related COPD and its relation to the severe risk of COPD and airway cancers | I | 0.732 | 0.389 | 0.643 | 0.407 | 0.241 | 0.321 |
| 0.525 |
| 213 | Studying value-based COPD care and identifying important values for patients and society to achieve in COPD care (in line with Machteld Huber’s ‘positive health’). | III | 0.574 | 0.370 | 0.519 | 0.429 | 0.224 | 0.621 |
| 0.495 |
| 212 | Identification of non-coding RNAs that contribute to COPD pathophysiology and development of inhalable ncRNA-based medicines for treatment of COPD symptomology | II | 0.712 | 0.385 | 0.667 | 0.389 | 0.278 | 0.321 |
| 0.510 |
| 211 | Validating of objective and subjective clinical outcomes specific for disease modifying therapies | III | 0.558 | 0.346 | 0.589 | 0.519 | 0.259 | 0.500 |
| 0.461 |
COPD – chronic obstructive pulmonary disease, LABA – long-acting β-agonist, LAMA – long-acting muscarinic antagonist; GOLD – Global Initiative for Chronic Obstructive Lung Disease (acronym for guidelines B/D)
*Overall Research Priority Score used for the ranking is given in bold.
Top 3 research ideas by research criteria
| Rank | Research idea | Answerable? | Effective? | Feasible? | Deliverable? | Impact? | Equity? | Rps | Aea |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| 1 | Studying whether inhaled corticosteroids increase risk of bacterial infections in COPD |
| 0.661 | 0.984 | 0.797 | 0.547 | 0.469 | 0.743 | 0.696 |
| 2 | Defining criteria for antibiotics use in acute COPD |
| 0.710 | 0.938 | 0.906 | 0.656 | 0.594 | 0.796 | 0.750 |
| 3 | Agreeing on COPD definition that should be used for research aiming to have an impact on clinical practice globally |
| 0.424 | 0.879 | 0.667 | 0.242 | 0.712 | 0.649 | 0.735 |
|
| |||||||||
| 1 | Developing new strategies (including new combinations of pharmacological and non-pharmacological strategies) to improve smoking cessation | 0.952 |
| 0.790 | 0.790 | 0.903 | 0.806 | 0.868 | 0.779 |
| 2 | Identifying optimal ways to detect smokers at risk of developing COPD and why only some of them seem to be at risk | 0.803 |
| 0.625 | 0.550 | 0.703 | 0.594 | 0.699 | 0.627 |
| 3 | Improved understanding of COPD risk factors and their association with COPD incidence and exact effects | 0.894 |
| 0.984 | 0.797 | 0.734 | 0.734 | 0.834 | 0.770 |
|
| |||||||||
| 1 | Improved understanding of COPD risk factors and their association with COPD incidence and exact effects | 0.894 | 0.859 |
| 0.797 | 0.734 | 0.734 | 0.834 | 0.770 |
| 2 | Studying whether inhaled corticosteroids increase risk of bacterial infections in COPD | 1.000 | 0.661 |
| 0.797 | 0.547 | 0.469 | 0.743 | 0.696 |
| 3 | Identifying optimal screening method for COPD in primary care | 0.938 | 0.773 |
| 0.924 | 0.667 | 0.848 | 0.853 | 0.814 |
|
| |||||||||
| 1 | Identifying optimal diagnostic approach for COPD in low-resource settings | 0.938 | 0.742 | 0.813 |
| 0.703 | 0.875 | 0.835 | 0.779 |
| 2 | Identifying optimal screening method for COPD in primary care | 0.938 | 0.773 | 0.969 |
| 0.667 | 0.848 | 0.853 | 0.814 |
| 3 | Conducting trials to explore if early palliative care improves health outcomes in people with advanced COPD | 0.919 | 0.650 | 0.968 |
| 0.400 | 0.633 | 0.748 | 0.691 |
|
| |||||||||
| 1 | Identifying strategies that are effective and cost-effective in reducing anxiety and depression among individuals with COPD | 0.933 | 0.583 | 0.919 | 0.800 |
| 0.742 | 0.816 | 0.672 |
| 2 | Developing new strategies (including new combinations of pharmacological and non-pharmacological strategies) to improve smoking cessation | 0.952 | 0.967 | 0.790 | 0.790 |
| 0.806 | 0.868 | 0.779 |
| 3 | Identifying feasible and effective modes of delivery of pulmonary rehabilitation in low-resource settings | 0.935 | 0.667 | 0.935 | 0.903 |
| 0.903 | 0.861 | 0.779 |
|
| |||||||||
| 1 | Defining the most affordable, accurate and reliable diagnostic process for respiratory symptoms in low-resource settings based on evidence | 0.891 | 0.758 | 0.823 | 0.917 | 0.742 |
| 0.844 | 0.755 |
| 2 | Identifying feasible and effective modes of delivery of pulmonary rehabilitation in low-resource settings | 0.935 | 0.667 | 0.935 | 0.903 | 0.823 |
| 0.861 | 0.779 |
| 3 | Identifying approached to scale-up of delivery of effective pulmonary rehabilitation in low resource settings to meet the burden of breathlessness | 0.900 | 0.672 | 0.933 | 0.850 | 0.817 |
| 0.845 | 0.730 |
COPD – chronic obstructive pulmonary disease